Viking Therapeutics: Wall Street’s Bullish Bet on a GLP-1 Challenger
Published on 11/28/2025 at 12:38 | Redaktion boerse-global.de
As U.S. markets operated on a shortened post-Thanksgiving schedule, research departments remained active, with Viking Therapeutics generating significant analyst enthusiasm. The biopharmaceutical company finds itself at the center of attention following Leerink Partners’ reaffirmation of their optimistic outlook, maintaining a $118 price target that suggests substantial growth potential from current trading levels near $36.27.
The pharmaceutical sector’s race to develop effective weight-loss treatments has created a market opportunity measured in trillions of dollars. Currently, industry giants Eli Lilly and Novo Nordisk maintain dominant positions with their GLP-1 agonist therapies. Viking Therapeutics aims to disrupt this established dynamic with its investigational compound VK2735, a dual-acting agent that simultaneously targets both GLP-1 and Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
